EW Q3 2021 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$49B

Q3 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.3B+14.8% YoY

Gross Profit

$1.0B77.0% margin

Operating Income

$407M31.1% margin

Net Income

$340M26.0% margin

EPS (Diluted)

$0.54

QoQ Revenue Growth

-4.8%

Cash Flow

Operating Cash Flow

$532M

Free Cash Flow

$471M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$8.2B

Total Liabilities

$2.6B

Stockholders' Equity

$5.5B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.1B	+14.8%
Gross Profit	$1.0B	$854M	+18.2%
Operating Income	$407M	$351M	+16.0%
Net Income	$340M	$325M	+4.6%

Revenue Segments

Transcatheter Heart Valves

$858M65%

Surgical Heart Valve Therapy

$217M17%

Critical Care

$213M16%

Transcatheter Mitral And Tricuspid Therapies

$22M2%

Geographic Segments

UNITED STATES

$753M57%

Europe

$291M22%

Rest of World

$140M11%

JAPAN

$126M10%